49
Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Embed Size (px)

DESCRIPTION

Antidysrhythmic Drugs. Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology). Antidysrhythmic drugs. Definition:  ความผิดปกติของอัตราการเต้นหรือจังหวะการเต้นของหัวใจ Symptom:  Palpitation  Dizziness  Syncope Diagnosis:  EKG (ECG). action potential (AP) ของ cardiac cell. - PowerPoint PPT Presentation

Citation preview

Page 1: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Vilasinee HirunpanichB. Pharm., M.Sc In Pharm(Pharmacology)

Page 2: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Definition:

ความผิ�ดปกติ�ของอ�ติราการเติ�นหร�อจั�งหวะการเติ�นของห�วใจั

Symptom:

Palpitation

Dizziness

Syncope

Diagnosis:

EKG (ECG)

Page 3: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)
Page 4: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

action potential (AP) ของ cardiac cell

Phase 0

Phase 2

Phase 3

Phase 4

Page 5: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)
Page 6: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

ชน�ดของ Dysrhythmia

Atrial arrhythmias

Supraventricular arrhythmias

Ventricular arrhythmias

Page 7: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

กลไกการเกด dysrhythmias

1. การผิ�ดปกติ�ของการสร�างส�ญญาณ ไฟฟ�าห�วใจั

(Abnormal impulse generation)

2. การผิ�ดปกติ�ของทิ�ศทิางการน!าส"ง ส�ญญาณไฟฟ�าห�วใจั

(Abnormal impulse conduction)

Conduction delay or block

Re-entry

Page 8: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

1. การผิ�ดปกติ�ของการสร�างส�ญญาณไฟฟ�าห�วใจั

Automaticity มี เซลล�อ��นๆที่ �ไมี�ใช่� SA-node เป็�นตั�วก�าหนดให�เกด

การส่�งส่�ญญาณไฟฟ$าห�วใจ เช่�น Purkinje fiber

ส่าเหตั&อ��นๆเช่�นsympathetic nerve system stimulation Ex.

beta-stimulation

K+ imbalance เช"นภาวะ hypokalemia

hypoxia

การกระติ%�นของ catecholamine

Page 9: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

2. การผิ�ดปกติ�ของทิ�ศทิางการน!าส"งส�ญญาณไฟฟ�าห�วใจั

การน!าส"งส�ญญาณไฟฟ�าห�วใจัในทิ�ศทิางทิ&'ผิ�ดปกติ�

ลั�กษณะของการเก�ดHeart block (AV-block)- เก�ดจัากการทิ!าลัายของ

conducting system การเก�ด re-entry ค�อ การเก�ดการกระติ%�นใหม"ในทิ&'เด�ม

หลั�งจัากการเก�ด refractory period

Page 10: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Re-entry

Page 11: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Abnormal electrocardiogram

Page 12: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

1. กด automaticity โดย การลัด slope ของ phase 4 depolarization เพิ่�'ม threshold ของการเก�ดส�ญญาณไฟฟ�าห�วใจัให�ม&ค"า

ส-งข./น

2. ป็ร�บที่ศที่างการน�าไฟฟ$าห�วใจให�เป็�นป็กตั กดการน!าส�ญญาณไฟฟ�าห�วใจัทิ&'ผิ�ดปกติ� เพิ่�'ม refractory period (effective refractory

periods)

Page 13: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)
Page 14: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Mechanisms Sodium channel blockadeBlockade of sympathetic autonomic effect in heartProlongation of the effective refractory periodCalcium channel blockade

Page 15: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Group of antiarrhythmic drugs

Class I: Sodium channel blockers

(Potent local anesthetic)

ลดการเกด phase O จ)งมี ผลลดexcitability, conduction velocityClass IA:

Quinidine, Procainamide, Disopyramide

Class IB:

Lidocaine, Tocainide, Mexiletine, Phenytoin

Class IC:

Flecainide

Page 16: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Class II: Sympatholytics drugs

Beta-blockers

Class III: Prolongation of the effective refractory period

Amiodarone, Sotalol, Bretylium

Class IV: Calcium channel blockers

Verapamil, Diltiazem, Bepridil

(not nifedipine)

Group of antiarrhythmic drugs (cont)

Page 17: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Pacemaker current

Fast inward current (Na+)

Slow inward current (Ca2+)

contraction

Beta-agonist

Class I

Class IV

Beta-agonistClass II

Class II

Phase 4

Phase 0

Phase 2

Re-entry Class III, IA, IB

Page 18: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Class I

Class IA Quinidine, procainamide, disopyramide

MechanismReduced rate of fast inward Na+ current during

phase 0

action potential (delay repolarization)

-Blockade of cardiac sodium channel

-Decrease conduction velocity in atria, ventricle and His-purkinje system

Page 19: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Class IA (cont)

ฤที่ธิ์-ที่างเภส่�ช่วที่ยาslowing impulse of conduction velocity

ลัด phase 4 depolarization ectopic pacemaker cell

เพิ่�'ม ventricular effective refractory periods

Immediate speed of association with activated/inactivated Na+ channel

Page 20: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Quinidine

Prototype ของยากลั%"ม class IA ยาม&ฤทิธิ์�2 anticholinergic effect ร"วมด�วย อาจัทิ!าให�ห�วใจั เติ�นเร3วข./น ซึ่.'งอาจัเพิ่�'มความเส&'ยงติ"อการเก�ด arrhythmia

มากข./นWiden QRS complex( by slowing depolarization of ventricle) & prolong QT interval (by delaying ventricular repolarization)

สามารถด-ดซึ่.มได�ด&จัาก GI & ข�บออกทิางป7สสาวะยาม&ฤทิธิ์�2เป8นด"างอ"อนด�งน�/นในภาวะทิ&'ป7สสาวะเป8นกรดมากข./นจัะทิ!าให�ยาถ-กข�บออกได�มากข./น ม& therapeutic index ติ!'า

Supraventricular and venticular dysrhythmia

Page 21: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Anticholinergic effect (Atropine like effect)

induced reflex tachycardia

(prevent by prior giving beta-blocker)

Pro-arrhythmic activity

Page 22: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

ToxicityHeart: ยาม&ผิลัย�บย�/ง vagal effect ซึ่.'งเพิ่�'ม

sympathetic response ในห�วใจั, AV block เปลั&'ยนแปลัง EKG ทิ!าให� prolong QT interval

others: GI..…..diarrhea, GI upset cinchonism.......tinnitis, headache,

nausea, vertigo, disturbed vision (quinidine syncope)

rash, edema, fever

Page 23: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Drug interactions

Digoxin (quinidine ไลั"ทิ&' digoxin จัากbinding sites)

Warfarin

Phenytoin

phenobarbital

Page 24: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Procainamide

การออกฤทิธิ์�2คลั�ายก�บยา quinidine แติ"ม&anticholinergic effect น�อยกว"าN-acetylprocainamide เป8น active metabolized ถ-กก!าจั�ดโดย hepatic metabolism

ม&อาการข�างเค&ยงติ"อ GI น�อยกว"า quinidine การใช�ยาในระยะยาวอาจัทิ!าให�เก�ด

agranulocytosis, neutropenia หร�อ lupus erythematosus like syndrome.(idiosyncracy)RX: atrial and ventricular dysrhythmias

Page 25: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Disopyramide ฤทิธิ์�2คลั�ายก�บ quinidine แติ"ม& antimuscarinic

effects มากกว"าWiden QRS and QT-interval

ม&ฤทิธิ์�2 Negative inotropic actions, severe hypotension ซึ่.'งเป8นข�อจั!าก�ดในการใช�ก�บผิ-�ป:วย

ทิ&'ม& CHF อาการข�างเค&ยงส"วนมากเก�ดจัากฤทิธิ์�2

Atropine-like effects เช"น dry mouth, blurred vision, urinary retention, dry mouth.RX; Ventricular dysrhythmia ไม"น�ยมใช�เป8นfirst line drug.

Page 26: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Class IBLidocaine, tocainide, mexiletine, phenytoin

Pharmacological action

Accelerate repolarization and have no effect on EKG

Page 27: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

LidocaineBlock Na ChannelReduce automaticity in ventricle and His-purkinje fiberAccelerate repolarization (shortens action potential duration) Potent suppressor of abnormal cardiac activityNo significant impact on EKGNo anticholinergic effect

Page 28: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Lidocaine (cont.)Extensively first pass metabolism

use IV only

จั�ดเป8นยาทิ&'ปลัอดภ�ย (therapeutic dose 1.5-5 g/ml)

การใช�ยาในขนาดส-งอาจัทิ!าให�เก�ด hypotension

ADR ติ!'า แติ"อาจัเก�ดอาการเช"น drowsiness, tremor, nausea, hearing disturbance, slurred speech, convulsion, paresthesia

ถ�อเป8น agent of choices ในการร�กษา ventricular dysrhythmia, #cardiac surgery& digoxin toxicity

Lidocaine is not active against supraventricular dysrhythmias.

Page 29: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Tocainide and mexiletine เป8นอน%พิ่�นธิ์;ของยา lidocaine

ออกฤทิธิ์�2เหม�อน lidocaine, not change EKGRX: ventricular dysrhythmia

สามารถใช�ได�ทิาง oral route เพิ่ราะไม"เก�ด first pass hepatic metabolism.Adverse effects: GI disturbancesNeurologic disorders: tremor, blurred

vision, lethargy, nausea.Rash, agranulocytosis (rare)Tocainide เก�ด fetal bone marrow aplasia,

pulmonary fibrosis

Page 30: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Phenytoin เป8นยาก�นช�กทิ&'ม&ฤทิธิ์�2ในการร�กษา arrhythmia ได�

ย�บย�/ง Na channel, reduce automaticity (ventricle), no effect on EKG

ADR: sedation, hypotension, prodysrhythmia

ร�กษา arrhythmia โดยเฉพิ่าะทิ&'เก�ดจัาก digoxin-induced dysrhythmias (second choice ติ"อ

จัาก lidocain)

Page 31: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Class ICBlock cardiac Na channel, reduce conduction velocity

Delay ventricular depolarization and increase refractory period

May exacerbate existing dysrhythmias

Page 32: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

FlecainidePotent blocker of Na+ and K+- channelsProlong PR interval and widen QRS complexสามารถให�โดยว�ธิ์&ร�บประทิานได�May be prodysrhythmiaMay decrease myocardial contractilityShould not be used combine with beta-blocker or verapamilRX: reserved for severe ventricular dysrhythmia

Page 33: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

PropafenoneBlock at Na-channel similar to flecainide

Decrease conduction velocity

Prolong PR interval and QRS complex

May be prodysrhythmic agent

It has some structure similar to propranolol and possesses weak beta-blocking activity.

Should not be used in CHF, AV-block and asthma

Reserved for pats with life-threatening ventricular dysrhythmias

ADR: metallic taste, constipation

Page 34: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)
Page 35: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

ผิลัของการกระติ%�นทิ&' Beta-adrenergic

เพิ่�'ม pacemaker current

เพิ่�'ม Ca2+ current

เพิ่�'มการเก�ด delayed after depolarization (DAD) arrhythmia

Page 36: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Class II: beta-adrenoceptor blockers

Decrease myocardial contractilityDecrease automaticity in SA-node Decrease conduction velocity in AV-nodeProlong PR interval in EKGRX: Treating dysrhythmia caused by excessive sympathetic stimulation on heartADR: CHF, AV-block, sinus arrest, hypotension

Page 37: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Beta-blocker

ยาทิ&'ใช�ในการร�กษา cardiac arrhythmia

Esmolol (intraoperative, acute arrhythmia)

Propranolol

Acebutalol

ยาทิ&'ใช�ในการป�องก�น arrhythmia หลั�งจัากการ เก�ด Myocardia infraction

Metoprolol

Propranolol

timolol

Page 38: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)
Page 39: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Delay repolarization of fast potential

Prolong action potential duration and effective refractory period

Prolong QT interval

Amiodarone, Sotalol, Bretylium, Ibulide, dofetilide

Class III Prolongation of the effective refractory period

Page 40: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Amiodarone ย�บย�/งทิ&' Na+-channel, K+-channel แลัะ

weak blockade ทิ&' Ca2+-channelNoncompetitive inhibitor of beta-adrenoceptorCardiac effectSlow AV conduction Increase ventricular refractory periodReduce automaticity in SA-node, contractility

Extracardiac effectPeripheral vasodilation (alpha adrenoceptor-

blocking and Ca-channel blocking)

Page 41: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Amiodarone (cont)Prolong PR and QT interval, QRS wideningVery long half life (13-103 day)RX: Life-threatening ventricular dysrhythmia

Toxicity Highly lipid soluble and accumulated in many tissues

Ex. cornea (yellow-brown microcrystal), skin Cardio toxicity: AV-heart block and Torsade de pointes pulmonary fibrosis (The most serious effect) GI disturbance

DI: increase plasma level of warfarin, phenytoin, quinidine, procainamide Consider to use as last choice only for life threatening-ventricular dysrhythmia

Page 42: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

BretyliumBlockade of potassium channels in Pukinje fiber and ventricular muscleDelay repolarization and prolong action potential duration and effective refractory periods When first administered, it causes a transient increase in catecholamine release.

ADR: hypotension (common)Used only for short term therapy of severe ventricular dysrhythmias (refractory to conventional therapy)

Page 43: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

SotalolNonselective beta-blockerDelay repolarizationCombine properties of class II and IIIProdysrhythmic properties are pronounced.Toxicity: prolong repolarization and torsade de pointes, bradycardia, AV-block, CHF, brochospasm

Use in life-threatening ventricular dysrhythmia

Page 44: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Ibulide, dofetilide

Pure K-channel blocker

Toxicity: torsade de pointes

Page 45: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)
Page 46: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Class IV: calcium channel blockers

Verapamil, diltiazem, bepridil

Pharmacological actions

ลัด HR

ลัด AV-conduction velocity

ย�บย�/ง ventricular tachycardia

Page 47: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

VerapamilBlock both activated and inactivated Ca-channelReduced SA node automaticity, delay AV-node conduction, reduced myocardial contractilityProlong PR interval

Major indications: 1. Supraventricular tachycardia caused by AV-node reentry curcuit 2. slow ventricular rate in pts. With atrial fibrillation

Drug interaction: digoxin (increase risk of AV-block)

Toxicity: negative inotropic, AV block (large dose), constipation, hypotenion

Page 48: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Miscelleneous

AdenosineEnhance potassium conductance and inhibit cAMP-induced calcium influxDirectly inhibit AV nodal conductionProlong PR intervalShort half-life and duration of action then shorten ADR (less than 1 min)Flushing, shortness of breath, AV blockUse for terminating paraxyamal supraventricular tachycardia

DigoxinDecrease conduction through AV-node and automaticity in SA-nodeCan be prodysrhythmia be increasing automaticity in Purkinje fiberProlong PR interval and shorten QTUse only in supraventricular dysrhythmia

Page 49: Vilasinee Hirunpanich B. Pharm., M.Sc In Pharm(Pharmacology)

Magnesium

Unknown mechanism

Indicated in pts with digitalis-induced arrhythmia

1 g IV over 20 min

Further investigation for the full detail of action.

Potassium

Depress ectopic pacemakers

Slowing conduction